NCT01247428View on ClinicalTrials.gov

First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

March 31, 2016

Conditions
Coronary Artery Disease
Interventions
DEVICE

MiStent SES

The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).

Trial Locations (5)

1032

Auckland City Hospital, Auckland

Mercy Angiography Unit - Mercy Hospital, Aukland

Unknown

St. Vincent's Hospital Melbourne, Melbourne

Onze-Lieve-Vrouwziekenhuis Aalst (OLV Hospital), Aalst

Ziekenhuis Oost-Limburg, Genk

Sponsors
All Listed Sponsors
lead

Micell Technologies

INDUSTRY

NCT01247428 - First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease | Biotech Hunter | Biotech Hunter